Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Colorectal Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1604994

Predictive value of serum miR-21 and miR-122 expression on the efficacy of capecitabine combined with transcatheter hepatic arterial embolization chemotherapy for liver metastasis after colorectal cancer surgery in patients with colorectal cancer and construction and verification of nomograms

Provisionally accepted
Wenfang  MaWenfang Ma1Zukuan  ChangZukuan Chang1Shixing  LiShixing Li1Xiuhua  WangXiuhua Wang1Guangshao  CaoGuangshao Cao2Youjie  FanYoujie Fan1*
  • 1Xinxiang Central Hospital, Xinxiang, China
  • 2Henan Provincial People's Hospital, Zhengzhou, Henan Province, China

The final, formatted version of the article will be published soon.

Objective: To explore the predictive value of serum miR-21 and miR-122 expressions on the efficacy of capecitabine combined with TACE for the treatment of postoperative liver metastasis in colorectal cancer patients, and to construct a nomogram model for verification. Methods: A total of 252 patients who received this treatment from January 2021 to December 2023 were included in the study. The dataset was randomly split at a 7:3 ratio into a training set (n=181) and a validation set (n=71). Serum levels of miR-21 and miR-122 before treatment were detected and the relationship with clinical pathological characteristics was analyzed. Independent risk factors were screened by multivariate Logistic regression, and a nomogram model was constructed to evaluate efficacy. Results: In the training set, there were 86 cases with effective treatment and 95 cases with ineffective treatment after operation. Multivariate analysis showed that CEA, high serum miR-21 expression, low miR-122 expression, tumor size, BMI, and age were the independent risk factors for efficacy (P<0.05). The nomogram model exhibited C-indexes of 0.809 (training set) and 0.732 (validation set). Additionally, the average absolute errors of the calibration curves were 0.178 and 0.210, respectively. The Hosmer-Lemeshow test result was good. The Receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) of the model in predicting the efficacy was 0.810 (95% CI: 0.734-0.885) and 0.731 (95% CI:0.597-0.866) in the training set and the verification set, respectively. The sensitivities and specificities were 0.820, 0.716 and 0.600 and 0.714, respectively.The expression levels of serum miR-21 and miR-122 have predictive value for the efficacy of liver metastasis after colorectal cancer treatment. The nomogram model has good predictive performance, which can provide a reference for clinical decision-making. Furthermore, the identified predictive value of miR-21 and miR-122 provides a basis for exploring personalized combination therapies with targeted agents in future studies, which may help overcome the limitations of conventional chemotherapy.

Keywords: colorectal cancer, liver metastases, capecitabine, Transcatheter hepatic artery embolization chemotherapy, miR-21, miR-122

Received: 02 Apr 2025; Accepted: 26 Jun 2025.

Copyright: © 2025 Ma, Chang, Li, Wang, Cao and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Youjie Fan, Xinxiang Central Hospital, Xinxiang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.